Satellos Bioscience opens the market

Satellos, a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders, went public on the TSX. Frank Gleeson, Co-Founder and Chief Executive Officer, Satellos Bioscience, and his team joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange (TSX), to open the market.

Satellos is an alumnus of the CAAP® program and presented at the OBIO® Investment Summit.